Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoru Muto

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Current Opinion in Urology|February 21, 2015
Opportunities for targeted focal treatment in JapanMasaki Kimura, Satoru Muto, Shigeo Horie
BMJ Case Reports|March 31, 2022
Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplastyKosuke Kitamura, Shuji Isotani, Satoru Muto, et al.
BMJ Case Reports|December 30, 2023
Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapyKosuke Kitamura, Takahiro Nonami, Satoru Muto, et al.
Clinical and Experimental Nephrology|March 25, 2011
The relationship between renal volume and renal function in autosomal dominant polycystic kidney diseaseShino Tokiwa, Satoru Muto, Toshiyuki China, et al.
Clinical and Experimental Nephrology|February 27, 2015
Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)Akiko Nakajima, Yan Lu, Haruna Kawano, et al.
International Journal of Andrology|April 27, 2007
Testosterone decreased urinary-frequency in nNOS-deficient miceSatoru Muto, Mitsuko Yasuda, Yutaka Kamiyama, et al.
Clinical and Experimental Nephrology|June 5, 2021
Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension JapanSatoru Muto, Tadashi Okada, Yoshiyuki Shibasaki, et al.
Clinical and Experimental Nephrology|November 5, 2017
Novel semi-automated kidney volume measurements in autosomal dominant polycystic kidney diseaseSatoru Muto, Haruna Kawano, Shuji Isotani, et al.
Clinical and Experimental Nephrology|July 6, 2021
Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillanceToshio Mochizuki, Satoru Muto, Masateru Miyake, et al.
Anticancer Research|March 6, 2020
The Dual Function of Aryl Hydrocarbon Receptor in Bladder CarcinogenesisJingsong Yu, Yan Lu, Satoru Muto, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Current Opinion in Urology|February 21, 2015
Opportunities for targeted focal treatment in JapanMasaki Kimura, Satoru Muto, Shigeo Horie
BMJ Case Reports|March 31, 2022
Efficacy of pembrolizumab in a rare type of bladder cancer arising 25 years after augmentation cystoplastyKosuke Kitamura, Shuji Isotani, Satoru Muto, et al.
BMJ Case Reports|December 30, 2023
Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapyKosuke Kitamura, Takahiro Nonami, Satoru Muto, et al.
Clinical and Experimental Nephrology|March 25, 2011
The relationship between renal volume and renal function in autosomal dominant polycystic kidney diseaseShino Tokiwa, Satoru Muto, Toshiyuki China, et al.
Clinical and Experimental Nephrology|February 27, 2015
Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)Akiko Nakajima, Yan Lu, Haruna Kawano, et al.
International Journal of Andrology|April 27, 2007
Testosterone decreased urinary-frequency in nNOS-deficient miceSatoru Muto, Mitsuko Yasuda, Yutaka Kamiyama, et al.
Clinical and Experimental Nephrology|June 5, 2021
Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension JapanSatoru Muto, Tadashi Okada, Yoshiyuki Shibasaki, et al.
Clinical and Experimental Nephrology|November 5, 2017
Novel semi-automated kidney volume measurements in autosomal dominant polycystic kidney diseaseSatoru Muto, Haruna Kawano, Shuji Isotani, et al.
Clinical and Experimental Nephrology|July 6, 2021
Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillanceToshio Mochizuki, Satoru Muto, Masateru Miyake, et al.
Anticancer Research|March 6, 2020
The Dual Function of Aryl Hydrocarbon Receptor in Bladder CarcinogenesisJingsong Yu, Yan Lu, Satoru Muto, et al.
Pageof 13